Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nippon Chemiphar Parts Ways With Ranbaxy; Takes Over Generics Venture

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Nippon Chemiphar Dec. 8 announced a dissolution of its partnership with India's Ranbaxy Laboratories. A generic drug joint venture established by the two will become a Nippon Chemiphar wholly owned subsidiary

You may also be interested in...



Teva-Kowa Accelerates Japanese Generic Expansion With Taisho Acquisition

Teva-Kowa Pharma announced Dec. 24 it will purchase a majority stake in mid-size generic competitor Taisho Pharmaceutical Industries. The acquisition gives the joint venture immediate access to 220 generic products and 50 sales staff

Teva-Kowa Accelerates Japanese Generic Expansion With Taisho Acquisition

Teva-Kowa Pharma announced Dec. 24 it will purchase a majority stake in mid-size generic competitor Taisho Pharmaceutical Industries. The acquisition gives the joint venture immediate access to 220 generic products and 50 sales staff

Pfizer Leaps Into Japanese Generics Foray; Aims For 100 Generic Products By 2011

Pfizer's Established Products Business Unit, a branch in charge of invigorating off-patent drugs and leading generic drug activities, will establish commercial operations in Japan starting Dec. 1

Related Content

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel